Integrated pharmacokinetics and pharmacodynamics of epoprostenol in healthy subjectsNICOLAS, Laurent B; KRAUSE, Andreas; GUTIERREZ, Marcelo M et al.British journal of clinical pharmacology. 2012, Vol 74, Num 6, pp 978-989, issn 0306-5251, 12 p.Article

Identical twins with primary pulmonary hypertension: Beraprost vs epoprostenolROSENZWEIG, Erika Berman; SCHMITT, Kelly A; GAROFANO, Robert et al.Chest. 2004, Vol 125, Num 3, pp 1157-1160, issn 0012-3692, 4 p.Article

Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injuryDAHLEM, Peter; VAN AALDEREN, Wim M. C; DE NEEF, Marjorie et al.Critical care medicine. 2004, Vol 32, Num 4, pp 1055-1060, issn 0090-3493, 6 p.Article

SIDE EFFECTS OCCURRING DURING ADMINISTRATION OF EPOPROSTENOL (PROSTACYCLIN, PGI₂), IN MANPICKLES H; O'GRADY J.1982; BR. J. CLIN. PHARMACOL.; ISSN 0306-5251; GBR; DA. 1982; VOL. 14; NO 2; PP. 177-185; BIBL. 4 P.Article

Epoprostenol inhibits human platelet-leukocyte mixed conjugate and platelet microparticle formation in whole bloodTAMBURRELLI, Chiara; CRESCENT, Marilena; IZZI, Benedetta et al.Thrombosis research. 2011, Vol 128, Num 5, pp 446-451, issn 0049-3848, 6 p.Article

Pulmonary vasodilator testing and use of calcium channel blockers in pulmonary arterial hypertensionTONELLI, Adriano R; ALNUAIMAT, Hassan; MUBARAK, Kamal et al.Respiratory medicine. 2010, Vol 104, Num 4, pp 481-496, issn 0954-6111, 16 p.Article

Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung diseaseMINAI, Omar A; SAHOO, D; CHAPMAN, J. T et al.Respiratory medicine. 2008, Vol 102, Num 7, pp 1015-1020, issn 0954-6111, 6 p.Article

Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertensionSTICHELLEHNER, Leopold; PETKOV, Ventzislav; VONBANK, Karin et al.Chest. 2003, Vol 123, Num 4, pp 1293-1295, issn 0012-3692, 3 p.Article

Inhaled Epoprostenol During One-Lung VentilationRAGHUNATHAN, Karthik; ROY CONNELLY, Neil; ROBBINS, Larry D et al.The Annals of thoracic surgery. 2010, Vol 89, Num 3, pp 981-983, issn 0003-4975, 3 p.Article

Treatment of pulmonary arterial hypertension: The role of prostacyclin and prostaglandin analogsSAFDAR, Zeenat.Respiratory medicine. 2011, Vol 105, Num 6, pp 818-827, issn 0954-6111, 10 p.Article

Treatment of pulmonary arterial hypertension: A preliminary decision analysisHIGHLAND, Kristin B; STRANGE, Charlie; MAZUR, Joe et al.Chest. 2003, Vol 124, Num 6, pp 2087-2092, issn 0012-3692, 6 p.Article

Epoprostenol in the treatment of congestive heart failurePHILLIPS, B. B; GANDHI, A. J.American journal of health-system pharmacy. 1997, Vol 54, Num 22, pp 2613-2615, issn 1079-2082Article

CIGARETTE SMOKING DOES NOT ATTENUATE THE CARDIOVASCULAR EFFECTS OF EPOPROSTENOL (PROSTACYCLIN) IN HUMANSHASSAN S; MACDOUGALL IC; O'GRADY J et al.1982; BR. J. CLIN. PHARMACOL.; ISSN 0306-5251; GBR; DA. 1982; VOL. 14; NO 1; PP. 97-98; BIBL. 4 REF.Article

Intrapulmonary shunting in primary pulmonary hypertension: An observation in two patients treated with epoprostenol sodiumCASTRO, P. F; BOURGE, R. C; MCGIFFIN, D. C et al.Chest. 1998, Vol 114, Num 1, pp 334-336, issn 0012-3692Article

Epoprostenol treatment in children with severe pulmonary hypertensionLAMMERS, Astrid E; HISLOP, Alison A; FLYNN, Yvette et al.Heart (London 1996). 2007, Vol 93, Num 6, pp 739-743, issn 1355-6037, 5 p.Article

Small-dose epoprostenol decreases systemic oxygen consumption and splanchnic oxygen extraction during normothermic cardiopulmonary bypassBRAUN, Jan-Peter; SCHROEDER, Torsten; KONERTZ, Wolfgang et al.Anesthesia and analgesia. 2006, Vol 102, Num 1, pp 17-24, issn 0003-2999, 8 p.Article

Vasopressin during spinal anesthesia in a patient with primary pulmonary hypertension treated with intravenous epoprostenolBRAUN, Edward B; PALIN, Christopher A; HAGUE, Charles W et al.Anesthesia and analgesia. 2004, Vol 99, Num 1, pp 36-37, issn 0003-2999, 2 p.Article

Pulmonary response of normal human subjects to inhaled vasodilator substancesBRETT, S. J; CHAMBERS, J; BUSH, A et al.Clinical science (1979). 1998, Vol 95, Num 5, pp 621-627, issn 0143-5221Article

THE CARDIOVASCULAR AND PLATELET EFFECTS OF EPOPROSTENOL (PROSTACYLIN, PGI₂) ARE UNAFFECTED BY BETA -ADRENOCEPTOR BLOCKADE IN MANHASSAN S; PICKLES H; FISH A et al.1982; BR. J. CLIN. PHARMACOL.; ISSN 0306-5251; GBR; DA. 1982; VOL. 14; PP. 369-377; BIBL. 2 P.Article

Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case seriesENDERBY, C. Y; SOUKUP, M; AL OMARI, M et al.Journal of clinical pharmacy and therapeutics (Print). 2014, Vol 39, Num 5, pp 496-500, issn 0269-4727, 5 p.Article

Potent effects of aerosol compared with intravenous treprostinil on the pulmonary circulationSANDIFER, Brett L; BRIGHAM, Kenneth L; LAWRENCE, E. Clinton et al.Journal of applied physiology (1985). 2005, Vol 99, Num 6, pp 2363-2368, issn 8750-7587, 6 p.Article

Efficacy and safety of treprostinil: An epoprostenol analog for primary pulmonary hypertensionMCLAUGHLIN, Vallerie V; GAINE, Sean P; SIGMAN, Jeff et al.Journal of cardiovascular pharmacology. 2003, Vol 41, Num 2, pp 293-299, issn 0160-2446, 7 p.Article

Determination of epoprostenol sodium (prostaglandin I₂ sodium) and related prostaglandins in epoprostenol sodium bulk drug by high-performance liquid chromatographyBOWMAN, P. B; HARTMAN, P. A.Journal of chromatography. 1984, Vol 291, pp 283-290, issn 0021-9673Article

Inhaled Epoprostenol for the Treatment of Pulmonary Arterial Hypertension in Critically Ill AdultsBUCKLEY, Mitchell S; FELDMAN, Jeremy P.Pharmacotherapy. 2010, Vol 30, Num 7, pp 728-740, issn 0277-0008, 13 p.Article

Epoprostenol and home mechanical ventilation for pulmonary hypertension associated with chronic lung diseaseZAIDI, Ali N; DETTORRE, Michael D; CENEVIVA, Gary D et al.Pediatric pulmonology. 2005, Vol 40, Num 3, pp 265-269, issn 8755-6863, 5 p.Article